with rosacea, especially mild or moderate dry skin (for Studies 1 and 2, 63.0% and 57.0% for IVM 1%, and 59.3% and 60.0% for vehicle, respectively) and mild or moderate itching (57.3% and 49.4% for IVM 1%, and 45.4% and 49.1% for vehicle). At week 12 (last available data observed), the majority of subjects had none of the 3 cutaneous symptoms. A trend was observed in terms of absence of dryness in 83-86% of IVM 1% subjects vs 72-76% for vehicle, as well as for absence of itching in 82-85% for IVM 1% vs 70-78% for vehicle.
Patient-Reported Outcomes
Improvement after treatment was rated by subjects as “excellent†or “good†by 69% and 66.2% for IVM 1% compared to 38.6% and 34.4% for vehicle (P<.001), respectively (Figure 4).“Excellent†improvement was reported by 34.3% and 32.0% for IVM 1% vs 9.5% and 7.3% for vehicle.
After 12 weeks of treatment, improved QoL scores were observed for subjects in the IVM 1% compared to vehicle groups. For the DLQI, it is of note that no difference between treatment groups was observed at baseline. At the end of each study, more subjects in the IVM 1% group (about 53%) than vehicle (about 35%) considered that their disease had no effect on their overall QoL (P<.001). For RosaQoL ™, improvement in QoL from baseline was higher in both studies for IVM 1% (-0.64 ± 0.7 and -0.60 ± 0.6 vs -0.35 ± 0.5 for both vehicle groups (P<.001 and P=.001 for Studies 1 and 2, respectively).
